Clinical Trial Update: Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of MK-0646 in metastatic neuroendocrine tumors has completed and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• MK-0646 (dalotuzumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroendocrine Tumors, Metastatic Neuroendocrine Tumors | Phase 2 | Status: COMPLETED | Results posted: 2015-11-20